Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STIA-1001
- Development stage
- Preclinical
- Lead developer
- Staidson Biopharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
STIA-1001 is a monoclonal antibody developed by Staidson (Beijing) Biopharmaceutical Co., Ltd. that targets Toll-like receptor alpha (TLRα). TLRα is a member of the Toll-like receptor family, which plays a critical role in the innate immune system by detecting pathogen-associated molecular patterns (PAMPs) and initiating inflammatory signaling. STIA-1001 is designed to modulate these immune responses, with potential applications in treating infectious diseases and autoimmune disorders. It is currently in the early stages of development within Staidson's immunology and inflammation pipeline.
- Other names
- TLRα monoclonal antibody
Beyond the preview
Go deeper on STIA-1001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STIA-1001.